Ceruloplasmin and Iron Metabolism in HIV: A Review

Article · June 2024

CITATIONS
0

READS
4

2 authors:

Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,700 PUBLICATIONS **23,808** CITATIONS
SEE PROFILE

Priya Homa Chukwu
Rivers State University of Science and Technology
13 PUBLICATIONS **0** CITATIONS
SEE PROFILE

Elite Journal of HIV. Volume 2 Issue 6(2024), Pp. 1-12
https://epjournals.com/journals/EJHIV

Ceruloplasmin and Iron Metabolism in HIV: A Review

*Emmanuel Ifeanyi Obeagu[1] and Priya Homa Chukwu [2]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, Rivers State University, Port Harcourt, Rivers State, Nigeria.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Human immunodeficiency virus (HIV) infection significantly impacts iron metabolism, a critical aspect of cellular function and systemic health. Ceruloplasmin, a copper-containing ferroxidase enzyme, plays a pivotal role in maintaining iron homeostasis by oxidizing ferrous iron (Fe^2+) to ferric iron (Fe^3+), facilitating its transport by transferrin. The dysregulation of iron metabolism in HIV is mediated by chronic inflammation, increased hepcidin levels, and altered cytokine profiles, leading to iron sequestration and anemia. This review explores the intricate interactions between ceruloplasmin and iron metabolism in the context of HIV, highlighting their implications for disease progression and therapeutic interventions. In HIV-infected individuals, chronic inflammation elevates pro-inflammatory cytokines like IL-6 and TNF-α, which in turn increase hepcidin production. Elevated hepcidin levels inhibit intestinal iron absorption and promote iron retention in macrophages, disrupting normal iron metabolism. As an acute-phase reactant, ceruloplasmin is upregulated during inflammation, further complicating iron mobilization and storage. The resulting imbalance contributes to anemia, a common complication in HIV that exacerbates disease morbidity. Additionally, the oxidative stress associated with HIV and ceruloplasmin dysfunction can damage erythrocytes, reducing their lifespan and impairing erythropoiesis. Antiretroviral therapy (ART) has revolutionized HIV treatment, significantly improving patient outcomes. However, ART can also affect iron metabolism and ceruloplasmin levels, often inducing oxidative stress and modifying inflammatory responses. Understanding these effects is crucial for optimizing ART regimens and managing HIV-related metabolic disturbances. Potential therapeutic strategies include anti-inflammatory treatments, antioxidant
Citation: Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV, 2024; 2(6): 1-12

supplementation, and hepcidin modulation to restore normal iron metabolism and ceruloplasmin function.

Keywords: *Ceruloplasmin, Iron metabolism, HIV, Inflammation, Oxidative stress, Anemia, Antiretroviral therapy (ART)*

Introduction

Human immunodeficiency virus (HIV) continues to pose a significant global health challenge, with millions of people affected worldwide.[1] The virus targets the immune system, specifically CD4+ T cells, leading to immunodeficiency and increased susceptibility to opportunistic infections and certain cancers.[2] Beyond its direct effects on the immune system, HIV infection induces a range of metabolic disturbances, including significant alterations in iron metabolism. These disturbances can contribute to various complications, including anemia and increased oxidative stress, both of which negatively impact the quality of life and overall health of HIV-infected individuals.[3-5] Iron is an essential nutrient involved in various cellular processes, including oxygen transport, DNA synthesis, and electron transport.[6] The body tightly regulates iron metabolism to maintain a balance between iron uptake, storage, and utilization, thereby preventing both iron deficiency and iron overload. Key players in this regulatory network include proteins such as transferrin, ferritin, and ceruloplasmin. Ceruloplasmin, a copper-containing glycoprotein with ferroxidase activity, is particularly crucial for iron homeostasis. It facilitates the conversion of ferrous iron (Fe^2+) to ferric iron (Fe^3+), enabling its binding to transferrin for transport in the bloodstream.[7-9] In the context of HIV infection, the regulation of iron metabolism becomes disrupted due to chronic inflammation and immune activation. HIV-infected individuals often exhibit elevated levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). These cytokines stimulate the production of hepcidin, a hormone that regulates iron homeostasis by inhibiting intestinal iron absorption and promoting iron sequestration in macrophages. Elevated hepcidin levels result in decreased iron availability for erythropoiesis, the process of red blood cell production, contributing to the development of anemia in HIV-infected individuals.[10-12]

Ceruloplasmin, as an acute-phase reactant, is upregulated in response to inflammation. Its increased production during chronic HIV infection further complicates iron metabolism. While ceruloplasmin's primary role is to facilitate iron transport by oxidizing Fe^2+ to Fe^3+, its dysfunction in the inflammatory milieu of HIV can impair iron mobilization and storage. This dysfunction can exacerbate iron-related complications, such as anemia, by reducing the bioavailability of iron needed for effective erythropoiesis. Additionally, the antioxidant properties of ceruloplasmin, which help mitigate oxidative stress by scavenging free radicals, may be compromised in HIV, leading to increased oxidative damage.[13-16] Oxidative stress is a significant concern in HIV infection, as it contributes to cellular and tissue damage, inflammation, and progression of the disease.[17] Ceruloplasmin plays a crucial role in protecting cells from oxidative stress by neutralizing free radicals. However, the chronic inflammation and immune activation seen in HIV can overwhelm these protective mechanisms, resulting in elevated oxidative stress

levels. This increased oxidative stress can damage erythrocytes, shorten their lifespan, and impair erythropoiesis, further contributing to anemia and other complications in HIV-infected individuals. Antiretroviral therapy (ART) has revolutionized the management of HIV, transforming it from a fatal disease to a manageable chronic condition.[18] ART significantly improves the prognosis of HIV-infected individuals by suppressing viral replication and restoring immune function. However, ART can also influence iron metabolism and ceruloplasmin levels. Certain antiretroviral drugs have been associated with oxidative stress and alterations in inflammatory responses, which can impact ceruloplasmin activity and iron homeostasis. Understanding these effects is essential for optimizing ART regimens and managing the metabolic disturbances associated with HIV infection.

The interplay between ceruloplasmin, iron metabolism, and HIV infection highlights the need for comprehensive management strategies that address these metabolic challenges. Potential therapeutic approaches include anti-inflammatory treatments to reduce chronic inflammation and cytokine dysregulation, antioxidant supplementation to mitigate oxidative stress, and hepcidin modulation to enhance iron availability and ameliorate anemia. These strategies aim to restore normal iron metabolism, preserve ceruloplasmin function, and improve overall health outcomes for HIV-infected individuals. In addition to therapeutic interventions, ongoing research is crucial for further elucidating the mechanisms underlying the interactions between ceruloplasmin, iron metabolism, and HIV.[19] Understanding these mechanisms can inform the development of novel therapies and diagnostic tools that target specific aspects of iron dysregulation and oxidative stress in HIV. For instance, investigating the role of genetic variations in ceruloplasmin and other iron-regulatory proteins may provide insights into individual susceptibility to iron-related complications and guide personalized treatment approaches. Furthermore, the impact of HIV-related metabolic disturbances extends beyond anemia and oxidative stress.[20] Dysregulated iron metabolism can affect various organ systems, including the cardiovascular system, liver, and brain, potentially contributing to comorbidities such as cardiovascular disease, liver dysfunction, and neurocognitive impairments. Therefore, a holistic approach to managing HIV should consider the broader implications of iron dysregulation and oxidative stress, aiming to prevent and mitigate these comorbidities.

Ceruloplasmin

Ceruloplasmin is a crucial copper-containing glycoprotein primarily synthesized in the liver and secreted into the bloodstream.[21] It plays a multifaceted role in iron metabolism and exhibits significant antioxidant properties, contributing to its importance in maintaining systemic homeostasis. Understanding the structure and function of ceruloplasmin provides insight into its role in various physiological processes and its implications in disease states, including HIV infection. Ceruloplasmin is a large protein composed of 1,046 amino acids, with a molecular weight of approximately 132 kDa.[22] It belongs to the family of multicopper oxidases, containing six copper atoms per molecule, which are integral to its enzymatic activity. The protein is organized into three homologous domains, each contributing to the overall stability and function of the molecule. The copper atoms are distributed across these domains, playing critical roles in

electron transfer and redox reactions. The primary structure of ceruloplasmin includes multiple glycosylation sites, where carbohydrate chains are attached. These glycosylation modifications are essential for the protein's stability, solubility, and half-life in the plasma. The secondary and tertiary structures of ceruloplasmin are characterized by a series of alpha-helices and beta-sheets that fold into a compact, globular form, facilitating its interactions with other molecules and its enzymatic functions.

The primary function of ceruloplasmin is its ferroxidase activity, which involves the oxidation of ferrous iron (Fe^2+) to ferric iron (Fe^3+).[23] This enzymatic process is crucial for iron homeostasis, as Fe^3+ is the form of iron that can be bound and transported by transferrin, the main iron transport protein in the blood. By facilitating the conversion of Fe^2+ to Fe^3+, ceruloplasmin ensures that iron is efficiently mobilized from storage sites, such as the liver and macrophages, into the circulation for delivery to tissues where it is needed. Ceruloplasmin also exhibits significant antioxidant properties, protecting cells from oxidative stress. It acts as a scavenger of reactive oxygen species (ROS), including superoxide radicals, thus preventing oxidative damage to cellular components. This antioxidant function is particularly important in inflammatory conditions, where elevated ROS levels can cause extensive tissue damage. By mitigating oxidative stress, ceruloplasmin helps maintain cellular integrity and function. Although less well understood, ceruloplasmin is also involved in copper metabolism. It carries a substantial portion of the body's total copper content in the blood, facilitating the transport of this essential trace element to various tissues. Copper is a critical cofactor for numerous enzymes involved in processes such as energy production, connective tissue formation, and neurotransmitter synthesis. By binding and transporting copper, ceruloplasmin contributes to the proper distribution and utilization of this vital nutrient. Ceruloplasmin is classified as an acute-phase reactant, meaning its levels increase in response to inflammation or infection. During acute-phase reactions, ceruloplasmin synthesis is upregulated by inflammatory cytokines, such as interleukin-6 (IL-6). This increase in ceruloplasmin production is part of the body's broader response to inflammation, aimed at limiting damage and promoting healing. However, in chronic inflammatory conditions, such as HIV infection, persistently elevated ceruloplasmin levels can contribute to iron dysregulation and other metabolic disturbances. Alterations in ceruloplasmin levels and function have been implicated in various disease states. For instance, reduced ceruloplasmin activity is observed in Wilson's disease, a genetic disorder characterized by copper accumulation and toxicity. Conversely, elevated ceruloplasmin levels are associated with chronic inflammatory conditions, cardiovascular diseases, and neurodegenerative disorders. In the context of HIV, ceruloplasmin dysregulation contributes to iron metabolism disturbances, exacerbating complications such as anemia and oxidative stress.[24-26]

Iron Metabolism in HIV

Iron metabolism in the human body is a tightly regulated process essential for various physiological functions, including oxygen transport, DNA synthesis, and cellular respiration.[27] The disruption of iron homeostasis is a common occurrence in individuals infected with HIV, leading to significant clinical complications such as anemia and increased susceptibility to

infections. This section explores the mechanisms underlying iron metabolism dysregulation in HIV, the role of chronic inflammation, and the impact of antiretroviral therapy (ART) on iron homeostasis. HIV infection induces a state of chronic inflammation and immune activation, characterized by elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).[28] These cytokines play a pivotal role in the dysregulation of iron metabolism. IL-6, in particular, stimulates the production of hepcidin, a key regulator of iron homeostasis. Hepcidin is a peptide hormone produced by the liver that inhibits iron absorption from the intestine and promotes iron sequestration within macrophages and hepatocytes by degrading ferroportin, the only known cellular iron exporter. The elevation of hepcidin levels in response to chronic inflammation in HIV leads to decreased iron absorption from the diet and increased iron retention in storage sites, such as the liver and spleen. This results in reduced iron availability for erythropoiesis, the process of red blood cell production, contributing to the development of anemia. Anemia of chronic disease, also known as anemia of inflammation, is commonly observed in HIV-infected individuals and is characterized by low serum iron levels despite adequate or increased body iron stores.[29-31] The dysregulation of iron transport and storage in HIV is further complicated by alterations in the expression and function of key iron regulatory proteins. For instance, elevated levels of ferritin, an iron storage protein, are often observed in HIV-infected individuals as a response to increased hepcidin and inflammation. High ferritin levels indicate increased iron storage within cells, reducing the amount of iron available in the bloodstream. Additionally, transferrin saturation, which reflects the proportion of transferrin bound to iron, is often reduced in HIV, further indicating disrupted iron transport.[32-35]

Ceruloplasmin, an acute-phase protein with ferroxidase activity, is upregulated in response to the chronic inflammation associated with HIV infection.[37] While ceruloplasmin's primary function is to oxidize ferrous iron (Fe^2+) to ferric iron (Fe^3+) for binding to transferrin, its increased levels during inflammation can complicate iron metabolism. The dysregulated function of ceruloplasmin in HIV can impair iron mobilization from storage sites, exacerbating iron sequestration and contributing to anemia. Additionally, ceruloplasmin's antioxidant properties may be overwhelmed by the oxidative stress prevalent in HIV, further impacting iron homeostasis. Antiretroviral therapy (ART) has significantly improved the prognosis of HIV-infected individuals by suppressing viral replication and restoring immune function.[37] However, ART can also influence iron metabolism. Certain antiretroviral drugs, particularly those in the protease inhibitor class, have been associated with oxidative stress and mitochondrial toxicity. These effects can exacerbate the dysregulation of iron metabolism by increasing oxidative damage and altering the expression of iron regulatory proteins. ART can modulate the inflammatory response in HIV-infected individuals.[38] Effective viral suppression by ART reduces systemic inflammation and cytokine levels, potentially lowering hepcidin production and improving iron homeostasis. However, the extent of this improvement varies among individuals and depends on factors such as the duration of ART, adherence to treatment, and the presence of co-infections or other comorbidities.

The nutritional status of HIV-infected individuals plays a critical role in iron metabolism. Malnutrition, common in advanced HIV infection, can exacerbate iron deficiency. ART programs often include nutritional support and iron supplementation to address these deficiencies.[39]

However, iron supplementation in the context of HIV must be carefully managed, as excessive iron can promote oxidative stress and pathogen growth, including opportunistic infections. Anemia is a prevalent complication in HIV-infected individuals, with multifactorial etiology including iron deficiency, chronic inflammation, and bone marrow suppression. The impact of anemia on HIV progression and patient outcomes is significant, as it can exacerbate fatigue, reduce physical performance, and impair immune function.[40] Effective management of anemia in HIV requires a comprehensive approach that addresses the underlying causes, including iron metabolism dysregulation, nutritional deficiencies, and the inflammatory milieu.

Role of Ceruloplasmin in HIV-Associated Iron Dysregulation

Ceruloplasmin, a copper-containing glycoprotein with ferroxidase activity, plays a vital role in iron metabolism and antioxidant defense. In the context of HIV infection, the regulation and function of ceruloplasmin are significantly altered due to chronic inflammation and immune activation, leading to iron dysregulation.[41] This section delves into the mechanisms by which ceruloplasmin contributes to HIV-associated iron dysregulation and its clinical implications. HIV infection is characterized by persistent immune activation and chronic inflammation, leading to elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α).[42] IL-6, in particular, induces the hepatic synthesis of acute-phase reactants, including ceruloplasmin. As a result, ceruloplasmin levels are significantly increased in HIV-infected individuals as part of the body's response to ongoing inflammation. Ceruloplasmin's primary function is to facilitate the oxidation of ferrous iron (Fe^2+) to ferric iron (Fe^3+), a form suitable for binding to transferrin, the main iron transport protein in the blood. This conversion is essential for the proper mobilization of iron from storage sites in the liver and macrophages into the circulation. In HIV-infected individuals, the increased ceruloplasmin levels might initially seem beneficial for maintaining iron transport. However, the inflammatory milieu and subsequent hepcidin upregulation can impair ferroportin function, the iron exporter on cell surfaces. This impairment hampers the release of iron from cells, leading to iron sequestration and reduced availability for erythropoiesis.

Hepcidin, a key regulator of iron homeostasis, is also upregulated in response to chronic inflammation in HIV.[43] Elevated hepcidin levels lead to the internalization and degradation of ferroportin, reducing iron efflux from macrophages and enterocytes. Although ceruloplasmin is capable of oxidizing iron for transport, the concurrent high levels of hepcidin in HIV infection limit the release of iron into the bloodstream. This situation results in iron being trapped within cells, contributing to anemia of chronic disease commonly seen in HIV patients. Ceruloplasmin has potent antioxidant properties, capable of scavenging reactive oxygen species (ROS) and protecting tissues from oxidative damage. HIV infection exacerbates oxidative stress due to increased ROS production and impaired antioxidant defenses.[44] Elevated ceruloplasmin levels, therefore, represent a protective response to counteract oxidative stress. However, the persistent oxidative environment in HIV can overwhelm ceruloplasmin's antioxidant capacity, leading to cellular damage, particularly in erythrocytes. This damage can shorten the lifespan of red blood cells and impair erythropoiesis, further contributing to anemia. Beyond its role in iron metabolism

and antioxidant defense, ceruloplasmin also influences immune function. It modulates the activity of immune cells, including macrophages and T cells, which are crucial in the body's response to HIV infection. Alterations in ceruloplasmin levels and function can impact the overall immune response, potentially affecting the progression of HIV disease and the body's ability to control opportunistic infections. The advent of antiretroviral therapy (ART) has dramatically improved the prognosis for HIV-infected individuals by suppressing viral replication and restoring immune function. However, ART can influence ceruloplasmin levels and iron metabolism. Certain antiretroviral drugs, particularly protease inhibitors, have been associated with increased oxidative stress and changes in inflammatory responses. These effects can modify ceruloplasmin activity and further complicate iron homeostasis. Monitoring ceruloplasmin levels and iron parameters in patients on ART is essential for managing potential metabolic complications.

Therapeutic Implications and Future Directions

The dysregulation of iron metabolism in HIV-infected individuals, driven by chronic inflammation and altered ceruloplasmin function, presents significant clinical challenges.[6] Addressing these challenges requires a comprehensive approach that includes targeted therapies to correct iron imbalances, reduce inflammation, and manage oxidative stress. This section discusses the therapeutic implications and potential future directions for improving iron homeostasis and overall health outcomes in HIV-infected individuals. Chronic inflammation is a central factor in HIV-associated iron dysregulation.[46] Pro-inflammatory cytokines such as IL-6 and TNF-α drive hepcidin production, leading to iron sequestration and anemia. Anti-inflammatory therapies, including cytokine inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs), may help mitigate this effect. For instance, tocilizumab, an IL-6 receptor antagonist, has shown promise in reducing hepcidin levels and improving anemia in inflammatory diseases. Applying such therapies in HIV could potentially enhance iron mobilization and alleviate anemia. Oxidative stress is exacerbated in HIV infection, impacting both ceruloplasmin function and iron metabolism.[47] Antioxidant supplementation, including vitamins C and E, selenium, and N-acetylcysteine (NAC), can help reduce oxidative damage and improve overall antioxidant defenses. These antioxidants can support ceruloplasmin's role in mitigating oxidative stress, protecting erythrocytes from damage, and enhancing erythropoiesis. Clinical trials are needed to evaluate the efficacy and safety of these supplements specifically in the context of HIV.

Elevated hepcidin levels are a key contributor to iron sequestration in HIV. Modulating hepcidin activity could restore normal iron homeostasis. Hepcidin antagonists or inhibitors, such as monoclonal antibodies targeting hepcidin or its receptor ferroportin, represent promising therapeutic approaches. Research into small molecule inhibitors and other biologics that can downregulate hepcidin production or block its action is ongoing. These therapies hold the potential to increase iron availability for erythropoiesis and reduce anemia. While ART has transformed HIV management, its impact on iron metabolism and ceruloplasmin function requires careful consideration.[48] Certain antiretroviral drugs, particularly protease inhibitors, can induce oxidative stress and affect inflammatory responses. Personalized ART regimens that minimize these adverse effects while maintaining viral suppression are essential. This may involve selecting antiretroviral

agents with favorable profiles regarding oxidative stress and inflammation or adjusting dosages to balance efficacy and side effects. Nutritional status plays a crucial role in managing iron metabolism in HIV-infected individuals. Comprehensive nutritional support, including balanced diets rich in iron and other essential nutrients, is fundamental. In cases of iron deficiency, careful iron supplementation is necessary. However, supplementation must be managed to avoid exacerbating oxidative stress or promoting pathogen growth. Intravenous iron formulations or oral iron supplements with controlled release mechanisms can be considered to optimize iron bioavailability and minimize side effects.

Given ceruloplasmin's pivotal role in iron oxidation and antioxidant defense, therapies aimed at enhancing its function could be beneficial. Approaches to increase ceruloplasmin activity or stabilize its structure might improve iron mobilization and reduce oxidative stress. Gene therapy or protein engineering techniques could be explored to enhance ceruloplasmin expression or function in HIV-infected individuals. Additionally, monitoring ceruloplasmin levels could serve as a biomarker for assessing inflammation and iron status, guiding therapeutic interventions. An integrative approach combining multiple therapeutic strategies may offer the best outcomes for managing iron dysregulation in HIV.[49] This could involve a combination of anti-inflammatory agents, antioxidants, hepcidin modulators, and optimized ART regimens, tailored to the individual needs of each patient. Multidisciplinary care teams, including infectious disease specialists, hematologists, and nutritionists, are essential for implementing such comprehensive management plans. Elucidating the detailed mechanisms by which ceruloplasmin and hepcidin interact in the context of HIV-associated inflammation and iron dysregulation. Developing and testing new therapeutic agents, including hepcidin inhibitors, anti-inflammatory drugs, and antioxidants, in clinical trials involving HIV-infected individuals. Identifying reliable biomarkers for monitoring iron status, inflammation, and oxidative stress in HIV, which can guide personalized treatment approaches. Conducting long-term studies to assess the impact of therapeutic interventions on iron metabolism, anemia, and overall health outcomes in HIV-infected populations.

Conclusion

The dysregulation of iron metabolism in HIV-infected individuals is a multifaceted issue intricately linked to chronic inflammation, oxidative stress, and altered ceruloplasmin function. Ceruloplasmin plays a critical role in iron homeostasis through its ferroxidase activity and antioxidant properties, yet its function is significantly impacted by the persistent inflammatory environment characteristic of HIV infection. Elevated hepcidin levels, driven by inflammation, lead to iron sequestration and reduced availability for erythropoiesis, resulting in anemia and related complications. Therapeutic strategies aimed at addressing these challenges must adopt a holistic approach, integrating anti-inflammatory therapies, antioxidant supplementation, and hepcidin modulation to restore balanced iron metabolism. Personalized antiretroviral therapy (ART) regimens, nutritional support, and careful iron supplementation are also crucial components of effective management. The potential of ceruloplasmin as a therapeutic target offers an additional avenue for intervention, with the possibility of enhancing its function to improve iron mobilization and reduce oxidative stress.

Citation: Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV, 2024; 2(6): 1-12

References

1. Parekh BS, Ou CY, Fonjungo PN, Kalou MB, Rottinghaus E, Puren A, Alexander H, Hurlston Cox M, Nkengasong JN. Diagnosis of human immunodeficiency virus infection. Clinical microbiology reviews. 2018;32(1):10-128.
2. Alimonti JB, Ball TB, Fowke KR. Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. Journal of general Virology. 2003;84(7):1649-16461.
3. Obeagu EI, Omar DM, Omar U. Leukaemia burden in Africa. Int. J. Curr. Res. Biol. Med. 2023; 1:17-22.
4. Obeagu EI, Gnanavel K. An Insight on Acute Myeloid Leukemia: Pediatric Perspective. Journal home page: http://www. journalijiar. com. 2022;10(03).
5. Obeagu EI, Nakyeyune S, Muhimbura E, Owunna TA, Uwakwe OS. Evaluation of haematological manifestations in patients with acute myeloid leukaemia in a tertiary hospital in Uganda. Madonna University Journal of Medicine and Health Sciences. 2022;2(3):58-63.
6. Zhang C. Essential functions of iron-requiring proteins in DNA replication, repair and cell cycle control. Protein & cell. 2014;5(10):750-760.
7. Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Psychiatric Disorders: A Review. Elite Journal of Laboratory Medicine. 2023;1(1):43-53.
8. Obeagu EI, Obeagu GU. Ceruloplasmin and HIV-Associated Pulmonary Complications: A Review. Elite Journal of Health Science. 2023;1(1):51-62.
9. Obeagu EI. Ceruloplasmin and HIV-Associated Hematological Abnormalities: A Review. Elite Journal of Medicine. 2023;1(1):31-44.
10. Obeagu EI, Obeagu GU. The Impact of Body Mass Index (BMI) on Immune Function in Leukemia Patients Living with HIV: A Review. Elite Journal of Immunology. 2024;2(4):73-92.
11. Obeagu EI. Understanding Body Mass Index Variations and Clinical Outcomes in Leukemia Patients with HIV. AIDS: A Review. Elite Journal of Health Science. 2024;2(4):59-72.
12. Obeagu EI. Exploring the Impact of Body Mass Index on Quality of Life in Leukemia Patients Living with HIV: A Review. Elite Journal of Haematology, 2024; 2 (5).:39-54.
13. Obeagu EI. Ceruloplasmin and HIV-Associated Malignancies: A Review. Elite Journal of Health Science. 2023;1(1):38-50.
14. Obeagu EI. Ceruloplasmin and HIV-Associated Hepatic Complications: A Review. Elite Journal of Nursing and Health Science. 2023;1(1):39-51.
15. Obeagu EI. Ceruloplasmin and HIV-Associated Coagulopathies: A Review. Elite Journal of Laboratory Medicine. 2023;1(1):28-41.
16. Obeagu EI, Okoroiwu IL, Azuonwu O. An update on hypoxic regulation of iron homeostasis and bone marrow environment. Int. J. Curr. Res. Med. Sci. 2018;4(10):42-8.
17. Gil L, Martínez G, González I, Tarinas A, Álvarez A, Giuliani A, Molina R, Tápanes R, Pérez J, León OS. Contribution to characterization of oxidative stress in HIV/AIDS patients. Pharmacological research. 2003;47(3):217-224.

Citation: Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV, 2024; 2(6): 1-12

18. Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert review of clinical pharmacology. 2019;12(12):1129-1143.
19. Singh N, Haldar S, Tripathi AK, Horback K, Wong J, Sharma D, Beserra A, Suda S, Anbalagan C, Dev S, Mukhopadhyay CK. Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities. Antioxidants & redox signaling. 2014;20(8):1324-1363.
20. Kamvuma K, Hamooya BM, Munsaka S, Masenga SK, Kirabo A. Mechanisms and Cardiorenal Complications of Chronic Anemia in People with HIV. Viruses. 2024;16(4):542.
21. Puchkova LV, Babich PS, Zatulovskaia YA, Ilyechova EY, Di Sole F. Copper metabolism of newborns is adapted to milk ceruloplasmin as a nutritive source of copper: Overview of the current data. Nutrients. 2018;10(11):1591.
22. Vasilyev VB. Looking for a partner: ceruloplasmin in protein–protein interactions. Biometals. 2019;32(2):195-210.
23. Wong BX, Ayton S, Lam LQ, Lei P, Adlard PA, Bush AI, Duce JA. A comparison of ceruloplasmin to biological polyanions in promoting the oxidation of Fe2+ under physiologically relevant conditions. Biochimica et Biophysica Acta (BBA)-General Subjects. 2014;1840(12):3299-3310.
24. Obeagu EI, Elamin EA, Obeagu GU. The Impact of BMI on Treatment Outcomes in Leukemia Patients with HIV: A Review. Elite Journal of Haematology, 2024; 2 (4).:23-35.
25. Obeagu EI, Obeagu GU. The Impact of Obesity on Overall Survival in Leukemia Patients Living with HIV: A Review. Elite Journal of Laboratory Medicine. 2024;2(4):26-45.
26. Obeagu EI, Obeagu GU. The Nexus Between Obesity and Leukemia Progression in HIV-Positive Individuals: A Review. Elite Journal of Haematology. 2024;2(4):180-98.
27. Muckenthaler MU, Lill R. Cellular iron physiology. Iron Physiology and Pathophysiology in Humans. 2012:27-50.
28. Breen EC. Pro-and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome. Pharmacology & therapeutics. 2002;95(3):295-304.
29. Obeagu EI, Babar Q. Acute Myeloid Leukaemia (AML): The Good, the Bad, and the Ugly. Int. J. Curr. Res. Med. Sci. 2021;7(7):29-41.
30. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Dysfunction in HIV-Related Hematological Malignancies: A Review. Elite Journal of Haematology, 2024; 2 (4).:105-22.
31. Obeagu EI, Obeagu GU. GATA-1 and HIV-Associated Myelodysplastic Syndromes: Pathogenesis and Treatment Strategies. Elite Journal of Medicine. 2024;2(4):1-8.
32. Obeagu EI, Mbabazi A, Obeagu GU, Muhimbura E, Igwe MC, Owunna TA, Okafor CJ, Jakheng SP. Evaluation of Platelets And Some Inflammation Markers Of Patients With Acute Myeloid Leukaemia In A Tertiary Hospital In Uganda. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Oct 1;2(3):78-84.
33. Obeagu EI, Obeagu GU. Early Infant Diagnosis: Shielding Infants from HIV Transmission. Elite Journal of Health Science. 2023;1(1):12-22.

Citation: Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV, 2024; 2(6): 1-12

34. Obeagu EI, Obeagu GU. Securing Health: The Role of Early Infant Diagnosis in Preventing HIV in Newborns. Elite Journal of Public Health. 2023;1(1):12-22.
35. Obeagu EI, Obeagu GU. Protecting Generations: Early Infant Diagnosis's Role in Preventing HIV Spread. Elite Journal of Public Health. 2023;1(1):1-11.
36. Kallianpur AR, Gittleman H, Letendre S, Ellis R, Barnholtz-Sloan JS, Bush WS, Heaton R, Samuels DC, Franklin DR, Rosario-Cookson D, Clifford DB. Cerebrospinal fluid ceruloplasmin, haptoglobin, and vascular endothelial growth factor are associated with neurocognitive impairment in adults with HIV infection. Molecular neurobiology. 2019; 56:3808-3818.
37. Wilson EM, Sereti I. Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs. Immunological reviews. 2013;254(1):343-354.
38. Nabatanzi R, Cose S, Joloba M, Jones SR, Nakanjako D. Effects of HIV infection and ART on phenotype and function of circulating monocytes, natural killer, and innate lymphoid cells. AIDS research and therapy. 2018; 15:1-8.
39. Raiten DJ, Grinspoon S, Arpadi S. Nutritional considerations in the use of ART in resource-limited settings. Geneva: World Health Organization Department of Nutrition for Health and Development. 2005.
40. Kamvuma K, Hamooya BM, Munsaka S, Masenga SK, Kirabo A. Mechanisms and Cardiorenal Complications of Chronic Anemia in People with HIV. Viruses. 2024;16(4):542.
41. Milenkovic J, Djordjevic B, Stojanovic D, Dunjic O, Petrovski V. Blue moonlighting in the immune response: Roles of copper and ceruloplasmin in the pathogenesis of inflammation and immune-mediated diseases. Acta Medica Medianae. 2022;61(2).
42. Bourgeois C, Gorwood J, Olivo A, Le Pelletier L, Capeau J, Lambotte O, Béréziat V, Lagathu C. Contribution of adipose tissue to the chronic immune activation and inflammation associated with HIV infection and its treatment. Frontiers in Immunology. 2021; 12:670566.
43. Armitage AE, Stacey AR, Giannoulatou E, Marshall E, Sturges P, Chatha K, Smith NM, Huang X, Xu X, Pasricha SR, Li N. Distinct patterns of hepcidin and iron regulation during HIV-1, HBV, and HCV infections. Proceedings of the National Academy of Sciences. 2014;111(33):12187-1292.
44. del Valle LG, Hernández RG, Ávila JP. Oxidative stress associated to disease progression and toxicity during antiretroviral therapy in human immunodeficiency virus infection. J Virol Microbiol. 2013; 13:15.
45. Weiss G. Iron metabolism in the anemia of chronic disease. Biochimica et Biophysica Acta (BBA)-General Subjects. 2009;1790(7):682-693.
46. Obeagu EI. Iron Overload in HIV: Implications for Disease Management. Elite Journal of HIV. 2023;1(1):15-28.
47. Ianiro G, D'Ezio V, Carpinelli L, Casella C, Bonaccorsi di Patti MC, Rosa L, Valenti P, Colasanti M, Musci G, Cutone A, Persichini T. Iron Saturation Drives Lactoferrin Effects on Oxidative Stress and Neurotoxicity Induced by HIV-1 Tat. International Journal of Molecular Sciences. 2023;24(9):7947.

Citation: Obeagu EI, Chukwu PH. Ceruloplasmin and Iron Metabolism in HIV: A Review. Elite Journal of HIV, 2024; 2(6): 1-12

48. Levine AJ, Singh KK, Kallianpur AR. Genetic, epigenetic, and transcriptomic studies of NeuroAIDS. Global Virology II-HIV and NeuroAIDS. 2017:445-518.
49. Marques O, Weiss G, Muckenthaler MU. The role of iron in chronic inflammatory diseases: from mechanisms to treatment options in anemia of inflammation. Blood, The Journal of the American Society of Hematology. 2022;140(19):2011-2023.